Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the isoenzymes COX-1 and COX-2 of
cyclooxygenase (COX). Renal side effects (eg, kidney function, fluid and urinary electrolyte …

Glomerular diseases remain the leading cause of chronic and end-stage kidney disease.
Significant advances in our understanding of human glomerular diseases have been …

The antiproliferative effect of statins on mesangial cells could represent a new therapeutic
approach in glomerulonephritis. We studied in rat mesangial cells whether the …

The pathogenesis of membranous nephropathy (MN) involves in situ formation of
subepithelial immune deposits that produce glomerular injury by damaging and/or activating …

Approaching epidemic levels, diabetic kidney disease (DKD) is now the leading cause of
end‐stage renal disease (ESRD). Microalbuminuria is an early clinical marker of DKD that …

Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. Active
and passive Heymann nephritis (HN) in rats are valuable experimental models because …

Cyclooxygenase metabolizes arachidonic acid to a family of bio-active fatty acids
designated prostaglandins. Two isoforms of cyclooxygenase exist, designated COX1 and …

Prostaglandins are produced constitutively by many tissues in the body, including brain, gut,
and kidney, and their synthesis increases at sites of inflammation. Cyclooxygenase (COX) …

The understanding of cellular and molecular mechanisms involved in the pathogenesis of
membranous nephropathy (MN) has come from studies carried out in the Heymann nephritis …

Selective cyclooxygenase-2 (COX-2) inhibitors appear to have beneficial renoprotective
effects in most, but not all, renal disease conditions. The objective of our study was to …